Analysts Set Gain Therapeutics, Inc. (NASDAQ:GANX) Target Price at $8.67

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $8.6667.

A number of analysts recently weighed in on GANX shares. Roth Capital reissued a “buy” rating and issued a $10.00 price objective on shares of Gain Therapeutics in a research report on Friday, December 19th. BTIG Research reiterated a “buy” rating and issued a $9.00 price target on shares of Gain Therapeutics in a report on Wednesday, October 15th. Maxim Group raised their price target on Gain Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Monday, December 29th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a research note on Friday, December 19th.

Institutional Investors Weigh In On Gain Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its stake in Gain Therapeutics by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock worth $523,000 after acquiring an additional 8,251 shares in the last quarter. Marshall Wace LLP boosted its holdings in shares of Gain Therapeutics by 41.0% in the second quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock valued at $498,000 after purchasing an additional 80,407 shares during the period. Wealth Enhancement Advisory Services LLC bought a new position in Gain Therapeutics in the third quarter worth approximately $28,000. Benedict Financial Advisors Inc. increased its holdings in Gain Therapeutics by 55.6% during the 3rd quarter. Benedict Financial Advisors Inc. now owns 35,000 shares of the company’s stock worth $62,000 after purchasing an additional 12,500 shares during the period. Finally, JPMorgan Chase & Co. bought a new stake in Gain Therapeutics during the 3rd quarter valued at $47,000. 11.97% of the stock is owned by hedge funds and other institutional investors.

Gain Therapeutics Stock Up 1.2%

NASDAQ GANX opened at $2.44 on Friday. The company has a quick ratio of 2.52, a current ratio of 2.52 and a debt-to-equity ratio of 0.05. Gain Therapeutics has a 52 week low of $1.41 and a 52 week high of $4.34. The firm has a market capitalization of $93.84 million, a price-to-earnings ratio of -4.00 and a beta of 0.06. The company has a fifty day moving average of $3.02 and a two-hundred day moving average of $2.20.

Gain Therapeutics (NASDAQ:GANX) last announced its earnings results on Wednesday, November 12th. The company reported ($0.15) earnings per share for the quarter, meeting the consensus estimate of ($0.15). On average, analysts predict that Gain Therapeutics will post -1 earnings per share for the current year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.